TrianglePreemptive CIML NK Cell Therapy (NCT06138587)
Preemptive CIML NK Cell Therapy trial for Acute Myeloid Leukemia (NCT06138587). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia and related blood cancers that are at high risk of returning after a stem cell transplant.
The idea: a week after the transplant, give extra help against leftover disease. Natural killer cells from a related donor are exposed to signaling proteins called cytokines in the lab, which makes them memory-like. They are infused with five injections of interleukin-2.
The first question is safety and the best dose. At Dana-Farber in Boston, Roman Shapiro leads this early study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.